Health
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have requested a re-examination of the recent negative opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the proposed dosing regimen of 2 mg/kg body weigh
About this update from Protalix Biotherapeutics, Inc. (de)
[{"type":"image","alt":"Chiesi Global Rare Diseases","displaySize":"","headline":null,"caption":"Chiesi Global Rare Diseases","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/9ef765237cc81158e8a73228d21a22b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Y0m00zdCu20g_4gFOTuo2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ef765237cc81158e8a73228d21a22b4","width":300,"height":138}},"lazy":false},{"type":"text","content":"-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --","length":80,"tagName":"p"},{"type":"text","content":"PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have requested a re-examination of the recent negative opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the proposed dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio® (pegunigalsidase alfa).","length":492,"tagName":"p"},{"type":"text","content":"The opinion concerns the request to add the E4W dosing regimen to the currently approved 1 mg/kg every 2 weeks (E2W) regimen. The existing marketing authorization for Elfabrio remains in effect pending the outcome of the re-examination procedure and subsequent decision by the European Commission (EC).","length":307,"tagName":"p"},{"type":"text","content":"Both Chiesi and Protalix remain fully committed to working closely with the EMA through the re-examination process and to addressing the high unmet medical needs of the Fabry community.","length":185,"tagName":"p"},{"type":"text","content":"Important Safety InformationIndication","length":39,"tagName":"p"},{"type":"text","content":"Elfabrio® (pegunigalsidase alfa-iwxj) is indicated for the treatment of adults with confirmed Fabry disease.","length":108,"tagName":"p"},{"type":"text","content":"Important Safety Information","length":28,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:99.7285%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;","val":[{"type":"text","content":...